Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Pompe Disease Market Growth in 2025?

In the past few years, there has been a consistent progression in the market size of Pompe disease. Projections suggest a growth from $1.74 billion in 2024 to $1.8 billion in 2025, indicating a compound annual growth rate (CAGR) of 3.6%. Factors contributing to the growth throughout the historic period include increased awareness and diagnosis, incentives from orphan drug designation, worldwide collaborations, research initiatives, and the influence of advocacy and support groups for patients.

What Is the Forecast for the Pompe Disease Market Size Through 2029?

In the coming years, we can anticipate substantial growth in the Pompe disease market, with expectations set at a value of $2.32 billion by 2029 and a compound annual growth rate (CAGR) of 6.5%. This projected growth over the forecast period can be ascertained to ongoing research and development initiatives, the broadening of newborn screening programs, progression in gene therapy, the rise in global investments geared toward rare diseases, drug development focused on patients, and the extension of clinical trials and research initiatives. The market also places a pronounced emphasis on personalized medicine strategies. Noteworthy trends for the forecast period encompass product innovation, advancements in technology, the putting into action of patient support schemes, the increasing acceptance of telemedicine for patient care, and collaborations aimed at broadening access programs.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11906&type=smp

What are the Key Market Players in Pompe Disease Market and How They’re Evolving?

Major companies operating in the pompe disease market include F. Hoffmann-La Roche AG, Sanofi S.A., Amicus Therapeutics Inc., Sangamo BioSciences Inc., Asklepios BioPharmaceutical Inc., Audentes Therapeutics Inc., Genethon, Maze Therapeutics Inc., Avidity Biosciences Inc., EpiVax Inc., M6P Therapeutics, Oxyrane UK Limited, Valerion Therapeutics LLC, Abeona Therapeutics Inc., BioMarin Pharmaceutical, Genzyme Corporation, Novartis AG, Ultragenyx Pharmaceutical, Aro Biotherapeutics Company, Akashi Therapeutics, Protalix BioTherapeutics, AVROBIO Inc., Catabasis Pharmaceuticals

What Are the Primary Growth Drivers in the Pompe Disease Market?

The escalating incidences of Pompe disease is anticipated to fuel the expansion of the market for the same. Pompe disease, alternatively termed as glycogen storage disease type II or acid maltase deficiency, is an uncommon genetic condition marked by the accumulation of glycogen (a sophisticated sugar molecule) in multiple body tissues, especially in muscles and organs. There are various treatments available for Pompe disease such as protein replacement therapy, alglucosidase alfa, and Nexviazyme for intravenous infusion. A surge in occurrences of Pompe disease will add impetus to the expansion of the Pompe disease market. For example, as per the updates of the European Medicines Agency Highlights in June 2022, a Europe-centered intergovernmental institution unveiled that about 224 infantile-onset, 471 juvenile-onset, and 20,490 adult-onset individuals in Europe may potentially develop Pompe disease due to mutations, based on the maximum birth incidence rate of 11.6 per 100,000. Hence, the escalating incidences of Pompe disease is primarily contributing to the expansion of the market for the same.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=11906&type=smp

What Are the Leading Segments in the Global Pompe Disease Industry?

The pompe disease market covered in this report is segmented –

1) By Type: Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Other Types

2) By Diagnosis: Blood Test, Genetic Test, Prenatal Test, Other Diagnosis

3) By Route Of Administration: Oral, Parenteral, Other routes Of administrations

4) By Therapy Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, Other Therapies

5) By End Users: Hospitals Or Clinics, Pharmaceuticals, Researchers, Other End-Users

Subsegments:

1) By Classic Infantile Form: Early-Onset Classic Pompe Disease, Severe Classic Pompe Disease

2) By Non-Classic Infantile Form: Mild Non-Classic Infantile Pompe Disease, Variants of Non-Classic Infantile Form

3) By Late-Onset Form: Adult-Onset Pompe Disease, Juvenile-Onset Pompe Disease

4) By Other Types: Asymptomatic Carriers, Other Rare Variants of Pompe Disease

What Are the Key Market Trends in the Pompe Disease Industry?

Advancements in product technology are emerging as a dominant trend in the pompe disease market, with leading companies utilizing these innovations to maintain their market standing. One such example occurred in September 2023 when Amicus Therapeutics, an American biopharmaceutical company, earned the U.S. Food and Drug Administration’s (FDA) endorsement for their two-component therapy for adults suffering from late-onset Pompe disease. This therapy involves Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) 65 mg capsules, both approved for those weighing over 40 kg. Pombiliti is a recombinant human GAA enzyme (rhGAA) developed for improved absorption into muscle cells, while Opfolda acts as an enzyme stabilizer to keep the enzyme steady in the blood. This FDA approval showcases the importance and impact of progress in science and medical fields.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report

What Is the Regional Outlook for the Pompe Disease Market?

North America was the largest region in the pompe disease market in 2024. The regions covered in the pompe disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11906

This Report Delivers Insight On:

1. How big is the pompe disease market, and how is it changing globally?

2. Who are the major companies in the pompe disease market, and how are they performing?

3. What are the key opportunities and risks in the pompe disease market right now?

4. Which products or customer segments are growing the most in the pompe disease market?

5. What factors are helping or slowing down the growth of the pompe disease market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model